Dyne Therapeutics Inc [DYN] stock prices are up 6.19% to $12.70 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DYN shares have gain 8.64% over the last week, with a monthly amount glided 5.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI started tracking the stock with Outperform rating on May 29, 2025, and set its price target to $46. On March 12, 2025, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $50 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $50 on March 07, 2025. Robert W. Baird initiated its recommendation with a Outperform and recommended $46 as its price target on December 13, 2024. RBC Capital Mkts started tracking with a Outperform rating for this stock on November 26, 2024, and assigned it a price target of $45. In a note dated October 24, 2024, JP Morgan downgraded an Neutral rating on this stock and revised its target price from $43 to $35.
The stock price of Dyne Therapeutics Inc [DYN] has been fluctuating between $6.36 and $47.45 over the past year. Currently, Wall Street analysts expect the stock to reach $47 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $12.70 at the most recent close of the market. An investor can expect a potential return of 270.08% based on the average DYN price forecast.
Analyzing the DYN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.53 and Total Capital is -0.58. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.10 points at the first support level, and at 11.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.11, and for the 2nd resistance point, it is at 13.53.
Ratios To Look Out For
It’s worth pointing out that Dyne Therapeutics Inc [NASDAQ:DYN]’s Current Ratio is 20.35. In addition, the Quick Ratio stands at 20.35 and the Cash Ratio stands at 13.94.
Transactions by insiders
Recent insider trading involved Scalzo Richard William, Officer, that happened on May 16 ’25 when 2479.0 shares were purchased. Officer, Beskrovnaya Oxana completed a deal on May 16 ’25 to buy 2589.0 shares. Meanwhile, Chief Commercial Officer Friedl-Naderer Johanna sold 143.0 shares on Mar 13 ’25.
